Evidence map›Paper›PMID 25601861›Full record

ReviewFrontiers in immunology2014

Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human Vγ9Vδ2 T Cells.

Christelle Harly, Cassie-Marie Peigné, Emmanuel Scotet

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Therapeutic avenues for γδ T cells in cancer.Journal for immunotherapy of cancer · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Alpaca (Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Butyrophilin3A proteins and Vγ9Vδ2 T cell activation.Seminars in cell & developmental biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Christelle HarlyLaboratory of Genome Integrity, Center for Cancer Research, National Cancer Institute , Bethesda, MD , USA ; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , USA.
Cassie-Marie PeignéUnité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, INSERM , Nantes , France ; University of Nantes , Nantes , France ; Unité Mixte de Recherche 6299, Centre National de la Recherche Scientifique , Nantes , France.
Emmanuel ScotetUnité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, INSERM , Nantes , France ; University of Nantes , Nantes , France ; Unité Mixte de Recherche 6299, Centre National de la Recherche Scientifique , Nantes , France.
Inserm · FRNantes Université · FRNational Cancer Institute · US

Funding

Early T lineage progenitorsR01AI059621 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BHANDOOLA, AVINASH · 2004 to 2013
$3.5M
Early T Lineage ProgenitorsR56AI059621 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GREENE, MARK I · 2014 to 2014
$400k
NIAID NIH HHS R01 AI059621NIAID NIH HHS R56 AI059621
6 · The paper itself

Abstract

In human beings, as well as in most non-human primates, the major peripheral γδ T cell subset, which accounts several percent of the whole lymphoid cells pool in adults, carries an heterodimeric TCR composed of Vγ9 and Vδ2 chains. Vγ9Vδ2 T cells are specifically and strongly activated by small organic pyrophosphate molecules termed phosphoantigens (phosphoAg). These low molecular weight compounds are metabolites that are produced by either microbes or endogenously, as intermediates of the mammalian mevalonate pathway, and can accumulate intracellularly during cell stress like transformation or infection. Despite the characterization of numerous natural and synthetic phosphoAg, the mechanism(s) underlying the unique and specific antigenic activation process induced by these compounds remains poorly understood. Activation is both TCR- and cell-to-cell contact-dependent, and results of previous studies have also strongly suggested a key contribution of membrane-associated molecules of primate origin expressed on target cells. The recent identification of B7-related butyrophilin (BTN) molecules CD277/BTN3A, and more precisely their BTN3A1 isoforms, as mandatory molecules in the phosphoAg-induced recognition of target cells by Vγ9Vδ2 T cells opens important opportunities for research and applications in this field. Here, we review the unusual and complex antigenic reactivity of human Vγ9Vδ2 T cells. We highlight the recent advances in our understanding of this process, and propose a model that integrates the type I glycoprotein BTN3A1 and its intracellular B30.2 domain as a physical intermediate implicated in the detection of dysregulated intracellular levels of phosphoAg and the sensing of cell stress by Vγ9Vδ2T cells. A better understanding of this mechanism will help optimize novel immunotherapeutical approaches that utilize the unique functional potential of this major γδ T cell subset.

Indexed as

antigenic activationbutyrophilinfunctionshuman γδ T lymphocytesphosphoantigens

Identifiers

PMID25601861
PMCPMC4283718
OpenAlexW1976452164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.